Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The board of directors accepted Hrosz’s resignation during a meeting held on 9 April and expressed appreciation for his significant contributions during his tenure. Hrosz will cease to be a key managerial personnel, senior management personnel, and a member of board committees at the close of business hours on 30 April 2025.
Further, the board approved Hrosz’s appointment as an additional non-executive director effective 1 May 2025, subject to shareholder approval, upon the recommendation of the nomination and remuneration committee (NRC).
Sanofi India is among the leading multinational companies in the Indian pharmaceutical market. It offers a wide array of medicines for therapy areas such as diabetes, cardiology, thrombosis, the central nervous system, and antihistamines.
The company’s consolidated net profit declined 33.7% to Rs 91.30 crore in Q4 FY25 as against Rs 137.70 crore reported in Q4 FY24. Total revenue from operations grew by 9.7% year on year (YoY) to Rs 514.90 crore in the quarter ended 31 March 2024.
Shares of Sanofi India rose 0.83% to Rs 6,100 on the BSE.